New Drug Approvals Archive - February 2009
Labeling Revision Approved: January 29, 2009
Read more: Isentress (raltegravir) FDA Approval History
ATryn (Antithrombin (Recombinant))
Date of Approval: February 6, 2009
Company: GTC Biotherapeutics, Inc.
Treatment for: Antithrombin III Deficiency
ATryn (Antithrombin (Recombinant)) is a recombinant form of human antithrombin for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.
Uloric (febuxostat) Tablets
Date of Approval: February 13, 2009
Company: Takeda Pharmaceutical Company Limited
Treatment for: Gout
Uloric (febuxostat) is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.
Read more: Uloric (febuxostat) FDA Approval History
Apidra (insulin glulisine)
New Dosage Form Approved: February 24, 2009
Symbicort (budesonide and formoterol)
New Indication Approved: February 27, 2009